| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/31/2003 | WO2003062205A1 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders |
| 07/31/2003 | WO2003062204A1 Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors |
| 07/31/2003 | WO2003062203A1 Method |
| 07/31/2003 | WO2003062201A1 1,4-dihydropyridine and pyridine compounds as calcium channel blockers |
| 07/31/2003 | WO2003062200A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 07/31/2003 | WO2003062192A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors |
| 07/31/2003 | WO2003062191A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062190A1 Compounds for modulating cell proliferation |
| 07/31/2003 | WO2003062189A1 N-(4-substituted phenyl)-anthranilic acid hydroxamate esters |
| 07/31/2003 | WO2003062186A1 Metal salts of (3s)-3-methoxycarbonyl-4-phenylbutyric acid and usage thereof |
| 07/31/2003 | WO2003062182A1 Method for stabilizing reduced coenzyme q10 and composition therefor |
| 07/31/2003 | WO2003062149A2 Antimicrobial composition including a triamine and a biocide |
| 07/31/2003 | WO2003061816A1 Apparatus and process for preparing crystalline particles |
| 07/31/2003 | WO2003061768A2 Use of a compound inactivating the kinase a protein in a composition containing a cosmetically acceptable medium in order to lighten the skin |
| 07/31/2003 | WO2003061767A1 Methods and compositions for the treatment of asthma and related disorders |
| 07/31/2003 | WO2003061766A1 Composition based on etyllinoleate and triethylcitrate for the treatment of seborrhea and acne |
| 07/31/2003 | WO2003061757A1 Transdermal/transmucosal preparations for electroporation |
| 07/31/2003 | WO2003061715A1 Infection-resistant medical devices |
| 07/31/2003 | WO2003061713A1 Nsaid-containing topical formulations that demonstrate chemopreventive activity |
| 07/31/2003 | WO2003061709A1 A method for preparing resinates |
| 07/31/2003 | WO2003061706A1 A weight management system for obese animals |
| 07/31/2003 | WO2003061705A1 Weight management system for obese animals |
| 07/31/2003 | WO2003061704A2 Combination therapy for the treatment of bacterial infections |
| 07/31/2003 | WO2003061703A1 Methods for treatment of multiple sclerosis with statins |
| 07/31/2003 | WO2003061702A1 Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunsuppressor and anti-inflammatory agent |
| 07/31/2003 | WO2003061701A2 Method of treating hemorrhagic shock or systemic inflammatory response syndrome |
| 07/31/2003 | WO2003061700A1 Remedies for chronic kidney diseases |
| 07/31/2003 | WO2003061699A1 Remedies for allergic diseases |
| 07/31/2003 | WO2003061698A1 6-fluorobicyclo[3.1.0]hexane derivatives |
| 07/31/2003 | WO2003061696A2 Systems and methods for photodynamic therapy |
| 07/31/2003 | WO2003061688A1 Novel analgesics |
| 07/31/2003 | WO2003061681A2 Proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 07/31/2003 | WO2003061673A1 Use of phosphorous dendrimers as medicaments. |
| 07/31/2003 | WO2003061672A1 Method of treatment of gastrointestinal disease and polymeric composition for use therein |
| 07/31/2003 | WO2003061671A1 Amido macrolides |
| 07/31/2003 | WO2003061670A1 Compounds useful as a3 adenosine receptor agonists |
| 07/31/2003 | WO2003061669A1 Use of alkylphosphocholines for the preventative treatment of protozoan diseases |
| 07/31/2003 | WO2003061668A1 Use of pulmonary surfactant for the prevention of infectious diseases |
| 07/31/2003 | WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 07/31/2003 | WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases |
| 07/31/2003 | WO2003061665A1 Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen |
| 07/31/2003 | WO2003061664A1 Orodispersible pharmaceutical composition comprising testosterone |
| 07/31/2003 | WO2003061663A1 Use of benzothiazepines having activity as inhibitors of ileal bile acid transport for reducing cholesterololemia |
| 07/31/2003 | WO2003061662A1 Orodispersible pharmaceutical composition comprising ivabradine |
| 07/31/2003 | WO2003061661A1 Orally dispersible pharmaceutical piribedil composition |
| 07/31/2003 | WO2003061660A1 Melanocortin receptor agonists |
| 07/31/2003 | WO2003061659A1 Treating stress response with chemokine receptor ccr5 modulators |
| 07/31/2003 | WO2003061658A1 Sigma receptor binder containing indanone derivative |
| 07/31/2003 | WO2003061657A1 5-ht3 receptor antagonists and methods of use |
| 07/31/2003 | WO2003061656A1 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/31/2003 | WO2003061655A1 2-aminothiazole allosteric enhancers of a1 adenosine receptors |
| 07/31/2003 | WO2003061654A1 Pramipexole for the treatment of hiv dementia |
| 07/31/2003 | WO2003061653A1 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| 07/31/2003 | WO2003061652A1 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors |
| 07/31/2003 | WO2003061651A1 Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| 07/31/2003 | WO2003061650A1 Orodispersible pharmaceutical composition comprising mitiglinide |
| 07/31/2003 | WO2003061649A1 Method for prevention of diseases in coeliac patients |
| 07/31/2003 | WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061647A1 Orodispersible pharmaceutical composition comprising 2-({2-methoxy-2- [3-(trifluoromethyl) phenyl]ethyl}amino) ethyl-4-(2-{ [2-(9h- fluoren-9-yl) acetyl]amino} ethyl)benzoate |
| 07/31/2003 | WO2003061646A1 Process for producing granules containing branched amino acids |
| 07/31/2003 | WO2003061645A1 Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders |
| 07/31/2003 | WO2003061644A1 Orodispersible pharmaceutical composition comprising agomelatine |
| 07/31/2003 | WO2003061643A1 Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes |
| 07/31/2003 | WO2003061642A1 Use of ambroxol in the treatment of chronic pains, cerebral excitotoxicity-related disorders and cardiac arrhythmias |
| 07/31/2003 | WO2003061641A1 Synergistic mixtures of o-phenylphenol and other nitrogen and aldehyde microbiocides |
| 07/31/2003 | WO2003061640A1 Higher-coordinate silicates |
| 07/31/2003 | WO2003061639A2 Use of glutathione synthesis stimulating compounds in reducing insulin resistance |
| 07/31/2003 | WO2003061638A2 Use of phosphodiesterase antagonists to treat insulin resistance |
| 07/31/2003 | WO2003061637A1 Compositions for pulmonary administration |
| 07/31/2003 | WO2003061636A2 Dna dosage forms |
| 07/31/2003 | WO2003061634A1 Sustained release pharmaceutical composition |
| 07/31/2003 | WO2003061632A1 Method of treatment of a patient requiring analgesia |
| 07/31/2003 | WO2003061631A1 Highly lubricious hydrophilic coating utilizing dendrimers |
| 07/31/2003 | WO2003061629A2 Dna dosage forms |
| 07/31/2003 | WO2003061626A1 Polymeric gel system for the controlled delivery of codrugs |
| 07/31/2003 | WO2003061623A1 Solid orally-dispersible pharmaceutical formulation |
| 07/31/2003 | WO2003061621A2 Dermal application system for aminolevulinic acid-derivatives |
| 07/31/2003 | WO2003061620A2 Peptide-carrying bodies for immune response |
| 07/31/2003 | WO2003061605A2 Methods of treatment of chronic immune disease |
| 07/31/2003 | WO2003061604A2 Novel alkyl/aryl hydroxy or keto thiepines. |
| 07/31/2003 | WO2003061598A2 Solenopsin a, b and analogs as novel angiogenesis inhibitors |
| 07/31/2003 | WO2003061597A2 Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| 07/31/2003 | WO2003061594A2 Methods and compositions for reducing the development of drug tolerance and/or physical dependence |
| 07/31/2003 | WO2003061593A2 Novel targeted compositions for diagnostic and therapeutic use |
| 07/31/2003 | WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 07/31/2003 | WO2003061584A2 Novel substituted benzimidazole dosage forms and method of using same |
| 07/31/2003 | WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | WO2003061579A2 Phthalocyanine and porphyrazine pharmaceutical compositions |
| 07/31/2003 | WO2003061578A2 Compositions for treatment or prevention of bioterrorism |
| 07/31/2003 | WO2003061577A2 Polyalkylene glycol with moiety for conjugating biologically active compound |
| 07/31/2003 | WO2003061574A2 Prevention of cisplatin induced deafness |
| 07/31/2003 | WO2003061573A2 Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo |
| 07/31/2003 | WO2003061572A2 Anti-inflammatory formulations |
| 07/31/2003 | WO2003061568A2 Methods and therapeutic compositions in the treatment of advanced cancer |
| 07/31/2003 | WO2003061567A2 Selective s1p1/edg1 receptor agonists |
| 07/31/2003 | WO2003061566A2 Anti-cancer combination and use thereof |
| 07/31/2003 | WO2003061560A2 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 07/31/2003 | WO2003061557A2 Levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| 07/31/2003 | WO2003061556A2 Ingestible capsaicin neutralizer |
| 07/31/2003 | WO2003061554A2 Composition containing moutan root bark extract as active ingredient |